Related Experiment Video
Updated: Mar 11, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Ipilimumab: from preclinical development to future clinical perspectives in melanoma
Paul Letendre1, Varun Monga1, Mohammed Milhem1
1Department of Hematology, Oncology & Blood & Marrow Transplantation & the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Abstract:
The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
10:03Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
Related Concept Videos
Tumor Immunotherapy
Preclinical Development: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...